← Eichor
Condition: Small Cell Neuroendocrine Carcinoma Of Bladder Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Small Cell Neuroendocrine Carcinoma Of Bladder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Phase 1 · 3 location(s) · Washington University School of Medicine · NCT06529822SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774DESTINY-PANTUMOUR04
Phase N/A · 18 location(s) · AstraZeneca · NCT0712400018F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06503146Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NA · 13 location(s) · European Organisation for Research and Treatment of Cancer - · NCT04498767Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Phase N/A · 1 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT05621837A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06228066Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT05312671A Study of VET3-TGI in Patients With Solid Tumors
Phase 1 · 7 location(s) · KaliVir Immunotherapeutics · NCT06444815SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Sol
Phase 1/Phase 2 · 5 location(s) · Molecular Partners AG · NCT07278479Integrated Cancer Repository for Cancer Research
Phase N/A · 42 location(s) · University of Nebraska · NCT02012699A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Phase N/A · 57 location(s) · Guardant Health, Inc. · NCT05059444Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161532Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Phase N/A · 8 location(s) · Elephas · NCT07327489A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT04923178
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.